Concomitant Antipsychotic Treatment
Customize your policy alerts
Sign up for Ambetter Nevada Policy NV.CP.PMN.10 alerts
Get alerted when Policy NV.CP.PMN.10 changes without checking for updates manually.
Monitor payer policy activity
Policy governing medical necessity and prior authorization for concomitant use of more than one second‑generation (atypical) antipsychotic for Medicaid members; affects contracted behavioral health prescribers who treat schizophrenia spectrum disorders and bipolar disorder with psychosis or severe symptoms.
No material clinical or coverage changes in this revision.
Medical Necessity Criteria
Refractory Schizophrenia Spectrum Disorder (Initial criteria)
Concomitant use of more than one atypical antipsychotic is medically necessary when ALL of the following criteria for Refractory Schizophrenia Spectrum Disorder are met:
Provider must submit documentation including office chart notes and lab results.
Refractory Bipolar Disorder with Psychosis/Severe Symptoms (Initial criteria)
Concomitant use of more than one atypical antipsychotic is medically necessary when ALL of the following criteria for Refractory Bipolar Disorder with Psychosis and/or Severe Symptoms are met:
Approval duration for initial approvals: 6 months; provider must submit supporting documentation including chart notes and labs.
Continuation Therapy
Continuation/extension criteria (must meet all):
Approval duration for continuation: 12 months. Provider must submit supporting documentation including chart notes and labs.
This policy does not authorize coverage for non‑FDA approved indications that are not expressly addressed here unless there is adequate supporting documentation in accordance with the plan’s off‑label use policy CP.PMN.53 or other applicable evidence of coverage documents. Additionally, prescriptions for concomitant atypical antipsychotics written by providers who are not behavioral health professionals are not authorized under this policy.
Use of multiple concomitant second‑generation (atypical) antipsychotics is limited to the specific diagnoses and clinical situations defined in this policy. Indications that are non‑FDA approved and not addressed in this policy require documentation meeting the off‑label use standard referenced above; absent that documentation such uses are not authorized. Likewise, prescriptions originating from clinicians who are not behavioral health medical professionals (BHMPs) are not authorized for concomitant atypical antipsychotic therapy.
Provider Requirements and Prior Authorization
Prior Authorization Required Beyond 60‑Day Cross‑Taper
Cross-tapering of two atypical antipsychotics is automatically approved for up to 60 days. Prior authorization is required for continued concomitant use beyond the 60-day cross‑taper period. The requesting provider must submit a prior authorization request to continue combination therapy.
- Automatic approval: up to 60 days for cross‑tapering two atypical antipsychotics
- Prior authorization required for concomitant use beyond 60 days
- Includes oral + injectable combinations of the same agent (e.g., Abilify + Abilify Maintena; risperidone + Risperdal Consta)
Required Medication Trials Before Concomitant Therapy
Concomitant use of more than one atypical antipsychotic may be authorized only for specific, treatment‑refractory diagnoses when documented trial requirements are met. Providers must document adherence and prior medication trials with durations and reasons for failure.
- Refractory Schizophrenia Spectrum Disorder: documented diagnosis (schizophrenia, schizoaffective, or schizophreniform) AND evidence of adequate trials of at least three individual antipsychotics from the AHCCCS Behavioral Health Drug Lists for 4–6 weeks at maximum tolerated dose with failure due to inadequate response, adverse reaction, or breakthrough symptoms; documentation that non‑adherence was not a contributing factor.
- Refractory Bipolar Disorder with Psychosis/Severe Symptoms: documented bipolar disorder AND evidence of adequate trials of at least four evidence‑based treatment options (which may include combination therapy of antipsychotics and mood stabilizers/anticonvulsants) for 4–6 weeks at maximum tolerated dose with failure due to inadequate response, adverse reaction, or breakthrough symptoms; documentation that non‑adherence was not a contributing factor.
- Approval duration when criteria met: 6 months
Required Supporting Documentation and Authorized Prescribers
Providers must submit supporting documentation with the prior authorization request, including office chart notes, medication trial history, and relevant laboratory results. Documentation must demonstrate that required trials and durations were completed and that non‑adherence did not account for treatment failures. Prescriptions must be written by contracted behavioral health professionals (BHMP); prescriptions from non‑behavioral health professionals are not authorized under this policy.
- Required documentation: office notes, lab results, medication trial details, and evidence of adherence assessment
- Prescriber requirement: must be a contracted behavioral health professional (BHMP) — prescriptions from non‑behavioral health professionals are not authorized
- Prior authorization requests must include rationale and evidence for continued concomitant therapy beyond the 60‑day cross‑taper
Medication Management
Medication management (concomitant antipsychotics)
Medication management rules for concomitant atypical antipsychotics:
Includes oral and injectable dosage forms of the same agent; prescribers must be contracted behavioral health professionals (BHMP).
Acronyms and Terms
Clinical Background
Concomitant use of more than one second‑generation (atypical) antipsychotic is considered only for patients with treatment‑refractory schizophrenia spectrum disorders or bipolar disorder with psychosis or severe symptoms, where single‑agent therapy and standard evidence‑based options have failed despite adequate trials. The policy requires documentation of multiple, adequate medication trials (for example, at least three individual antipsychotic trials for refractory schizophrenia and at least four evidence‑based treatment trials for refractory bipolar disorder), each lasting approximately 4–6 weeks at maximum tolerated dose, and evidence that medication nonadherence was not the cause of treatment failure. Cross‑tapering between agents is accommodated with an automatic approval period of 60 days; continued concomitant therapy beyond that period requires prior authorization and behavioral health prescriber oversight. Continuation approvals require documentation of a positive clinical response and, when applicable, may be authorized for up to 12 months (or 6 months for initial bipolar refractory approvals as specified).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.